Pre-Assessment

Please enable JavaScript in your browser to complete this form.
Name
Which of the following best represents your profession
1. Which of the following statements regarding the safety profile of once-weekly insulin efsitora alfa compared with the safety profile of once-daily insulin degludec is supported by the T2D clinical trial data?
2. A 62-year-old woman with poorly controlled T2D (A1C 8.3%), is started on weekly insulin after failing to achieve glycemic targets with oral agents. She weighs 80 kg and has a body mass index (BMI) of 28 kg/m2. Her fasting plasma glucose (FPG) levels from the past week range from 131 to 154 mg/dL. What is the most appropriate starting dose of weekly insulin for her?
3. Approximately how many missed basal insulin doses in a month were found to significantly impact glucose control?
4. Mr. Garcia, a 58-year-old with A1C 9.2%, is reluctant to start basal insulin. He expresses concerns about side effects (e.g., weight gain, hypoglycemia), guilt ("I’ve failed by needing insulin"), and uncertainty about self-titration. He also feels unsupported due to lack of feedback from past care. Which of the following strategies is most effective in addressing Mr. Garcia's concerns about starting insulin?
5. How confident are you in your ability to initiate basal insulin therapy with patients with T2D?
Scroll to Top